Follow sourced scientific, clinical, partnership, capacity, and financial developments. Factual summaries and business interpretations are presented separately.
Incremental research runs every 3 hours. Verified updates are published when qualifying developments are found. Editorial standards · RSS ↗
Circle Pharma nominated CID-165, an orally available macrocyclic cyclin D1 RxL inhibitor, as the development candidate for its second oncology program. Preclinical studies supported disruption of the cyclin D1–Rb interaction and activity alone or with other therapies. Candidate nomination is a discovery-to-development milestone, not IND authorization or evidence that human dosing has begun.
PeptiDream described an orally administered macrocyclic peptide inhibiting IL-17A/A, A/F, and F/F. Preclinical challenge studies showed CXCL1 suppression and skin distribution. The company is progressing toward IND-enabling work and exploring partnerships. Entry into its development portfolio does not mean human dosing has begun, and claimed biologic-like activity remains preclinical.
Biogen and Dayra announced a research collaboration to discover and optimize oral macrocyclic peptides for immunological targets. Dayra receives $50 million upfront and may receive candidate-acquisition payments and development milestones per program. Biogen would lead subsequent development, manufacturing, and potential commercialization. The agreement concerns early discovery rather than established clinical efficacy.
Sungening reported that its preclinical SG6001 oral cyclic peptide program for hyperlipidemia was included in Shenzhen’s strategic emerging industries support initiative for innovative drug technology. The announcement did not disclose an award amount or human results. Program support advances research resources rather than establishing clinical authorization, product approval, or completed commercial manufacturing.
Merck presented Phase 3 CORALreef HeFH results in adults with heterozygous familial hypercholesterolemia receiving background lipid-lowering therapy. Enlicitide reduced LDL-C by 59.4% versus placebo at week 24 and 61.5% at week 52. The overall safety profile was comparable with placebo. The study evaluated lipid changes rather than cardiovascular-event outcomes.
Merck reported Phase 3 CORALreef Lipids results showing a 55.8% placebo-adjusted LDL-C reduction at week 24 in the primary analysis. A post hoc reanalysis addressing biologically implausible baseline values estimated 59.7%. LDL-C reductions persisted through week 52. These lipid findings should not be equated with demonstrated reductions in cardiovascular events.
Continue your research
All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.
